SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal buys Cipla's i-pill for Rs 95 crore

25 Mar 2010 Evaluate

Piramal Healthcare bought Cipla’s oral contraceptive brand, i-pill, for Rs 95 crore, to achieve its target of trebling its over-the-counter (OTC) drug business in three years. i-pill is an emergency contraceptive brand, that recorded Rs 31 crore sales last year, and competes with Mankind Pharma’s Unwanted 72, in a fast-growing, Rs 100-crore Indian market.

The all-cash acquisition of the brand is part of Piramal’s efforts to grow its OTC drug business in India. Cipla sold the brand because it wishes to focus on its prescription products. Servicing just one OTC brand is not a good idea. It needs a large support system, which is better used by someone who has a basket of OTC products. Piramal will scout for more such acquisition in the OTC segment.

crackcrack

Piramal Ent - Amalga Share Price

1124.60 0.00 (0.00%)
22-Sep-2025 16:59 View Price Chart
Peers

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×